Compare DexCom, Inc. (DXCM) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs T Rowe Price Group Inc — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while T Rowe Price Group Inc trades at $119.27 (market cap $25.41B). The key difference: DexCom, Inc. and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays a 4.39% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TROW | |
|---|---|---|
Market Cap | $28.06B | $25.41B |
Sector | Health | Financials |
52-Week High | $89.53 | $120.16 |
52-Week Low | $54.84 | $86.19 |
Enterprise Value | $27.03B | $22.12B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
T. Rowe Price (TROW) trades at $119.13, up 2.64% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages and positive momentum indicators. Fundamentally, TROW maintains robust profitability with a 28.28% net margin and 19.31% ROE, supported by steady revenue growth to $7.31B in 2025. Recent news highlights AUM reaching $1.89 trillion in June 2026 and inclusion on Zacks Strong Buy lists for value and income stocks.
TROW presents a mixed outlook with solid fundamentals and bullish technicals offset by cautious analyst sentiment. Investment appeal lies in strong cash flow, dividend reliability, and undervaluation relative to earnings. Key risks include equity outflows, competitive pressures, and market sensitivity. While Wall Street consensus is neutral, the stock's current momentum and financial health suggest potential for upside if operational trends persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
